| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Medical Research Council Environmental Epidemiology Unit, University of Southampton (R.M.R., H.E.S., C.B.W., D.I.W.P.), SO16 6YD Southampton, United Kingdom; Department of Medical Sciences, University of Edinburgh (R.M.R., B.R.W.), Western General Hospital, Edinburgh, Scotland EH4 2XU, United Kingdom; Regional Endocrine Unit, Southampton General Hospital (P.J.W.), SO16 6YD Southampton, United Kingdom
Address all correspondence and requests for reprints to: Dr. R. M. Reynolds, MA MRCP, Molecular Medicine Centre, Western General Hospital, Edinburgh EH4 2XU, Scotland, United Kingdom. E-mail: r.reynolds{at}ed.ac.uk
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The mechanisms leading to variations in plasma cortisol action in subjects with glucose intolerance are unknown. Differences in glucose and/or insulin concentrations may be important: for example, insulin may modulate adrenal steroidogenesis by inhibiting 17,20-lyase, thereby favoring cortisol synthesis in preference to dehydroepiandrosterone and androstenedione (10). Insulin may also affect cortisol metabolism by decreasing the activity of 11ß-hydroxysteroid dehydrogenase type 1, which acts primarily as a reductase mediating conversion of inactive cortisone to active cortisol (11). Such effects may be important determinants of acute changes in plasma cortisol, for example during a glucose tolerance test. It is known that plasma cortisol levels fall during a glucose tolerance test (12, 13) and that this effect may differ in subjects with cardiovascular risk factors (14, 15). However, it is not known whether this reflects the circadian fall in circulating plasma cortisol and whether ingestion of glucose affects the response. We therefore performed a placebo-controlled study of the effect of oral glucose on circulating plasma cortisol. To further explore the associations between cortisol and glucose tolerance, we studied both subjects with glucose intolerance and normoglycaemic controls.
| Subjects and Methods |
|---|
|
|
|---|
We studied 40 men, aged 68 to 77 yr, selected from a well-characterized cohort from Hertfordshire who have participated in previous investigations of the relationships between early life events and subsequent Type 2 diabetes (16). The subjects were selected by their previous glucose tolerance data from 1991 with the aim of studying equal numbers with glucose intolerance and normal controls. None had a history of endocrine disease or had received systemic or topical glucocorticoid treatment within the previous 6 months. Ethical approval was obtained from East and North Hertfordshire Local Research Ethics Committee and written informed consent was obtained.
Clinical protocol
Following an overnight fast, subjects attended a local clinic at 0830 h for oral glucose tolerance tests. A 21-g butterfly cannula was inserted in an antecubital vein and after 30-min rest, a baseline blood sample was obtained. Subjects then drank either 75 g oral glucose (as 389 ml Traditional Lucozade Sparkling Glucose Drink) or placebo (identical in appearance and taste to Lucozade but containing no glucose, supplied by SmithKline Beecham). They returned a week later for a repeat test with the alternative solution in a single-blind cross-over design. Twenty-nine subjects (17 glucose intolerant, 12 controls) received glucose in the first phase, whereas 10 subjects (5 glucose intolerant, 5 controls) received placebo first. Venous blood was sampled from the cannula at 30, 60, 90, and 120 min following the glucose or placebo load. Placebo and glucose phases were separated by at least 1 week.
Laboratory methods
Blood samples were centrifuged, processed immediately and stored at -80 C for subsequent hormone analysis. RIAs were used to measure plasma cortisol using Guildhay antisera (17) and corticosteroid-binding globulin (CBG) (Medgenics Diagnostics, Fleurus, Belgium). Plasma glucose was measured by the hexokinase method.
Statistical methods
As the distributions of cortisol measurements were skewed, loge transformed variables were used in all analyses. Independent two-sample t tests were used to compare cortisol concentrations for control compared with glucose intolerant subjects. ANOVA for repeated measures was used to analyze the plasma cortisol measurements during the glucose tolerance test.
| Results |
|---|
|
|
|---|
11.1 mmol/L)], and 17 subjects as normal controls. Differences in plasma cortisol between controls and glucose intolerant subjects without glucose
In all subjects, plasma cortisol concentrations declined over the
120 min of the test following placebo. Glucose intolerant subjects had
significantly higher cortisol concentrations following placebo than
controls (P = 0.001) (Fig. 1
). This difference was most marked at
baseline and during the first 90 min of the test but was no longer
present at 120 min. The differences in cortisol between glucose
intolerant subjects and controls were not accounted for by variations
in CBG (data not shown).
|
Figure 2
shows that treatment with
an oral glucose load blunted the circadian fall in plasma cortisol in
both controls and glucose intolerant subjects (P =
0.002). There was no significant difference in the effect of the
glucose load in controls compared with those with glucose
intolerance (controls P = 0.02, glucose intolerant
P = 0.04, interaction P = 0.50).
|
0900 h plasma cortisol concentrations were significantly higher in
the first phase of the study than in the second phase in controls
(P = 0.01) (Fig. 3
).
However, in glucose intolerant subjects, 0900 h plasma cortisol
concentrations in the two-study phases were not different
(P = 0.18), as this measurement did not fall in the
second study phase.
|
Both plasma glucose and insulin concentrations were higher after treatment with glucose than placebo (P < 0.001) and were significantly higher in glucose intolerant subjects than controls. In contrast to the plasma cortisol concentrations, plasma glucose and insulin concentrations were no different in the two study phases in either glucose intolerant subjects or controls.
| Discussion |
|---|
|
|
|---|
Our findings accord with early reports showing that plasma cortisol concentrations fall during an oral glucose tolerance test (12, 13). It was not known whether this reflects the fall in circadian fall in plasma cortisol or whether glucose ingestion affects the response. We performed our studies in the morning when any alterations in circadian rhythm should be most clearly demonstrated. Indeed, we found higher plasma cortisol in subjects with glucose intolerance than controls during the first 90 min of the placebo phase of the study. Altered diurnal rhythms of salivary cortisol in subjects with glucose intolerance have been reported (9), and our finding is consistent with the previously reported associations between 0900 h plasma cortisol and glucose intolerance (5, 6). However, the difference between subjects with glucose intolerance and controls was no longer apparent at 120 min. This finding could explain why associations between cortisol measurements and glucose tolerance are still evident at 120 min following glucose in some reports (14) but to a lesser extent than the fasting measurements in others (15). The current study, therefore, implies that where two measurements of plasma cortisol are separated by 2 h, during which cortisol will fall due to diurnal variation, the timing of measurements is critical.
Despite the differences in circadian fall of plasma cortisol, the effect of glucose ingestion was to raise plasma cortisol in both normal and glucose intolerant subjects. Plasma and salivary cortisol concentrations rise following a meal (9), particularly if the meal is of high protein content (18), as protein ingestion stimulates pituitary ACTH secretion (19). Although it has previously been suggested that carbohydrate ingestion has little effect on the hypothalamic-pituitary-adrenal (HPA) axis (20), we have now demonstrated that an oral glucose load raises plasma cortisol. It remains unknown whether this is a consequence of the glucose load itself, or whether the associated insulin release affects cortisol metabolism (10, 11). Insulin may also act centrally on the HPA axis regulating drive, although results of studies to date are conflicting, either showing a decreased cortisol response to CRH following insulin infusion (21), or increased adrenocorticotrophic hormone (ACTH) secretion following supraphysiological hyperinsulinaemia (22). Likewise, the changes in cortisol induced by the glucose load could influence subsequent glucose and insulin metabolism. Manipulation of cortisol levels within the physiological range alters insulin sensitivity (23). And although subject to the limitations of measurement of hepatic glucose output in man, cortisol has been shown to impair insulin-dependent glucose uptake in the periphery and enhance gluconeogenesis in the liver (24, 25). However, as the effect of treatment with the glucose load did not differ between glucose intolerant subjects and controls, it would appear less likely that the hyperglycaemia or changes in insulin concentrations associated with glucose intolerance influenced the fall in cortisol concentrations during the test.
One alternative hypothesis to explain the elevated plasma cortisol during the glucose tolerance test is a response to stress. We attempted to reduce any effect of stress by conducting the study in familiar surroundings, with staff previously known to the subjects. Yet we have found that fasting plasma cortisol measured at the first phase attendance, and so arguably the most stressful visit, was significantly higher than that at the second phase in control subjects. Elevated plasma and salivary cortisol concentrations are observed in situations of increased perceived stress (9), and the stress of venepuncture is known to raise plasma cortisol (26). The effect of psychosocial stress on raising cortisol has also been reported to be greater after a glucose load (27).
Most interestingly, we found that glucose intolerant subjects also had high baseline plasma cortisol concentrations in the second phase of the study, indicating a lack of habituation to repeated stress. A similar lack of habituation of blood pressure and heart rate responses to repeated restraint stress is seen in spontaneously hypertensive rats compared with normal controls (28). Subjects with glucose intolerance have evidence of increased activation of the HPA axis (29), and so elevated plasma cortisol from stress of venous sampling would be consistent with enhanced drive to CRH, ACTH, and cortisol secretion from higher centers in these subjects. Lack of habituation to stress and increased activation of the HPA axis in subjects with glucose intolerance would support the hypothesis that chronic stress in man leads to development of cardiovascular risk factors. Such variations in HPA axis activity may also contribute to the observed relationships between psychosocial stress and subsequent cardiovascular disease (30).
In conclusion, this study supports the hypothesis that alterations in central regulation of the HPA axis may be an important mechanism underlying the development of glucose intolerance and subsequent cardiovascular disease.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 British Heart Foundation Senior Research Fellow. ![]()
Received May 16, 2000.
Accepted November 10, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Muller, N. Schweitzer, O. Johren, P. Dominiak, and W. Raasch Angiotensin II stimulates the reactivity of the pituitary-adrenal axis in leptin-resistant Zucker rats, thereby influencing the glucose utilization Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E802 - E810. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Haussmann, C. M. Vleck, and E. S. Farrar A laboratory exercise to illustrate increased salivary cortisol in response to three stressful conditions using competitive ELISA Advan Physiol Educ, March 1, 2007; 31(1): 110 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
D S Gardner, B W M Van Bon, J Dandrea, P J Goddard, S F May, V Wilson, T Stephenson, and M E Symonds Effect of periconceptional undernutrition and gender on hypothalamic-pituitary-adrenal axis function in young adult sheep. J. Endocrinol., August 1, 2006; 190(2): 203 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Gordon and K. H. McKeever Oral and intravenous carbohydrate challenges decrease active ghrelin concentrations and alter hormones related to control of energy metabolism in horses J Anim Sci, July 1, 2006; 84(7): 1682 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Misra, K. K. Miller, C. Almazan, K. Ramaswamy, W. Lapcharoensap, M. Worley, G. Neubauer, D. B. Herzog, and A. Klibanski Alterations in Cortisol Secretory Dynamics in Adolescent Girls with Anorexia Nervosa and Effects on Bone Metabolism J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4972 - 4980. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Banjanin, A. Kapoor, and S. G. Matthews Prenatal glucocorticoid exposure alters hypothalamic-pituitary-adrenal function and blood pressure in mature male guinea pigs J. Physiol., July 1, 2004; 558(1): 305 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Andrews, A. Kostaki, E. Setiawan, L. McCabe, D. Owen, S. Banjanin, and S. G. Matthews Developmental regulation of the 5-HT7 serotonin receptor and transcription factor NGFI-A in the fetal guinea-pig limbic system: influence of GCs J. Physiol., March 15, 2004; 555(3): 659 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Wake, E. Rask, D. E. W. Livingstone, S. Soderberg, T. Olsson, and B. R. Walker Local and Systemic Impact of Transcriptional Up-Regulation of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue in Human Obesity J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3983 - 3988. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Andrews, O. Herlihy, D. E. W. Livingstone, R. Andrew, and B. R. Walker Abnormal Cortisol Metabolism and Tissue Sensitivity to Cortisol in Patients with Glucose Intolerance J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5587 - 5593. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |